BioInno Technologies Completes Over RMB 10 Million Seed Financing to Advance Cancer Diagnostics and Therapeutics

Recently,Wuhan Baiyingnuo Biotechnology Co., Ltd. (hereinafter referred to as “Baiyingnuo Tech”) Announces Completion of Multi-Million RMB Seed Funding Round, this financing round was led byDongke Chuangxing、Wuhan Institute of BiotechnologyJoint Investment. The funds raised will be used forAdvancing the R&D and registration testing of multiple product pipelines at Baiyinno Technology, to accelerate the launch of the product pipeline and the acquisition of IND clinical trial approvals.

Baiyingnuo Technology was established in June 2021, dedicated to the screening and validation of novel targets for cancer immunotherapy, as well as preclinical research on antibody drugs and cell therapy products., while providing diagnostic and therapeutic services for immunotherapy in mid-to-late stage cancer, the company is also actively expanding into peptide drug research and development. In January 2022, the company signed a scientific research cooperation agreement with Tongji Hospital, affiliated with Tongji Medical College of Huazhong University of Science and Technology, to facilitate the smooth implementation of collaborative projects and potential translation of research outcomes.

Currently, the company has assembled a large team of experts, professors, and industrialization professionals from the fields of oncology, immunology, and medical laboratory science. Within the technical team, six members hold doctoral degrees, five have overseas study experience, and four have been selected for national-level high-level talent programs. Currently,Baiyinno Technology has established the only team in China with original innovation capabilities in cancer companion diagnostics.。

This July, the Baiyinuo Scientific Committee was established

Based on the current landscape of malignant tumor treatment and patient needs, Baiyingnuo Technology has independently developed two core products. Among them,“Innokang” PD-L1 Companion Diagnostic Kit, significantly improving detection specificity while maintaining high sensitivity, thereby enabling more precise diagnoses for patients with advanced-stage cancer and offering them hope for a cure."Innotai": A Novel Peptide Drug for Inhibiting Tumor Cell Metastasis, by inhibiting cancer cell activity and metastasis, fundamentally controlling the problem of pleural and ascitic effusion, and extending the survival period of patients with mid-to-late stage cancer.

Immunotherapy, known as the fourth major cancer treatment modality following surgery, radiotherapy, and chemotherapy. Among these, PD-1/PD-L1 therapy has become the most widely used form of cancer immunotherapy. However, existing diagnostic reagents lack sufficient sensitivity and have limited screening capability for patients who are not suitable for PD-1/PD-L1 therapy, resulting in wasted treatment time and substantial medical costs.

Baiyingnuo Technology’s independently developed PD-1/PD-L1 companion diagnostic in vitro diagnostic reagents can significantly improve the sensitivity of anti-PD-1/L1 immunotherapy efficacy, thereby more accurately identifying patients who truly benefit from PD-1/L1 immunotherapy.“Yinuokang” Predicts Response to Anti-PD-1/L1 Immunotherapy, Validated in Lung CancerEfficacy Sensitivity: 93%, significantly higher than the sensitivity of less than 60% seen in other existing companion diagnostic products.

Malignant pleural and ascitic effusion is one of the common complications in middle and late-stage cancer, and severe pleural or ascitic fluid can even be life-threatening. Often in clinical cases, patients who develop pleural and ascitic effusion have a survival period of less than 6 months. The current mainstream treatments for malignant pleural and ascitic effusion include diuretic therapy and hyperthermic perfusion therapy, neither of which can address the problem at its root.

Baiyingnuo Technology’s independently developed novel peptide drug, “Yingnuotai,”By inhibiting cancer cell activity and metastasis, malignant ascites and pleural effusion can be fundamentally controlled, thereby extending the survival of patients with advanced-stage cancer., alleviate patient suffering, and improve quality of life.

Li Runqing, General Manager of Baiyingnuo Technologystated: “Since its establishment, Baiyingnuo Technology has been dedicated to translating clinically validated technological innovations into industrial achievements in precision immunotherapy, offering hope for a cure even to patients with advanced-stage cancer. Looking ahead, we will continue to focus on the diagnostic and therapeutic needs of cancer, uphold the concept of precision medicine, and contribute to the advancement of human health.”

Zhu Zifang, Founder and General Manager of Dongke ChuangxingIt stated: “Amid the trend of population aging, the number of new cancer cases in China continues to rise. In recent years, an increasing number of cancer indications have been approved, and more immunotherapy drugs have been included in the National Reimbursement Drug List. Baiyingnuo Technology is poised to leverage this favorable momentum and enter a fast track of development. With the completion of this round of financing, Baiyingnuo Technology will also make greater contributions to the cause of human health.”

Dongke Chuangxing, founded in 2013, is a privately-owned venture capital firm currently managing multiple funds. It primarily invests in four key sectors: semiconductors, intelligent manufacturing, new materials, and life & health. Meanwhile, it is actively expanding into frontier fields such as optoelectronics, artificial intelligence, biotechnology, and medical devices. The firm focuses on early-stage tech startups at the angel, Pre-A, and Series A rounds. Notably, 95% of its portfolio companies have successfully secured subsequent funding rounds, with several having initiated their IPO processes.

Wuhan Baihui Huizhi Venture Capital Fund Partnership (L.P.) was jointly initiated by Wuhan Institute of Biotechnology Co., Ltd., Wuhan Optics Valley Bio-industry Base Construction Investment Co., Ltd., and Wuhan Baiying Bio-industry Investment Management Co., Ltd. The bio-industry fund completed its filing on November 27, 2018, and was officially unveiled and established on December 6. This fund primarily invests in bio-industry-related fields such as biopharmaceuticals, bio-agriculture, and bio-services, with a particular focus on projects incubated by the Wuhan Institute of Biotechnology. It leverages the demonstrative effect and amplifying role of government guidance funds while fostering a batch of strategic emerging industries centered on biotechnology, including biopharmaceuticals and medical devices, thereby generating social benefits. Meanwhile, the fund extensively invests in projects within the East Lake Technology Development Zone, striving to develop into an outstanding equity investment fund that maximizes returns for investors. With a fund size of RMB 50 million, it is entrusted to be managed by Wuhan Baiying Bio-industry Investment Management Co., Ltd., a subsidiary of the Institute.